Presbia to Participate in the XXXIV Congress of the European Society of Cataract & Refractive Surgeons and in the International Society of Presbyopia 2016

Presbia PLC (NASDAQ: LENS), an ophthalmic device company and leader in near-vision restoration will participate in the XXXIV Congress of the European Society of Cataract and Refractive Surgeons (ESCRS), Europe’s leading organization for cataract and refractive surgeons in Copenhagen on September 10^th through 14^th.

Dr. Wayne Crewe-Brown, a leading laser eye surgeon who has the most commercial experience with the Presbia Flexivue Microlens™ implant, will be participating in an instructional course on inlays.

Dr. Marco Fantozzi, a leading ophthalmological surgeon with over 10,000 refractive surgeries, including the first refractive surgery with a femto laser, will conduct a wet lab at Presbia’s booth at the Congress.

Both Drs. Crewe-Brown and Fantozzi are members of Presbia’s Medical Advisory Board.

Dr. Carl Stonecipher, a clinical investigator who is participating in the U.S. Food and Drug Administration pivotal study of the Presbia Flexivue Microlens, along with Dr. Crewe-Brown, will conduct presentations at the International Society of Presbyopia (ISOP) 8^th Annual Conference at the Tivoli Hotel & Congress Center on September 9^th in Copenhagen.

"ESCRS and ISOP are a great opportunity to affirm Presbia’s market leading presbyopia treatment to the surgical community. This is an ideal forum to increase key opinion leaders’ awareness of the excellent results that have been consistently reported globally by surgeons and patients using our Microlens as the treatment for near-vision loss,” said Todd Cooper, President and CEO of Presbia.

Please contact Presbia to request a meeting or wet lab.

Forward-Looking Statements

Information provided and statements contained in this press release that are not purely historical are forward-looking statements. Such forward-looking statements only speak as of the date of this press release and Presbia assumes no obligation to update the information included in this press release. Statements made in this press release that are forward-looking in nature may involve risks and uncertainties. Accordingly, readers are cautioned that any such forward-looking statements are not guarantees and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Although Presbia believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Unless otherwise required by law, Presbia also disclaims any obligation to update its view of any such risks or uncertainties or to announce publicly the result of any revisions to the forward-looking statements made in this press release.

About Presbia

Presbia PLC (NASDAQ:LENS) is an ophthalmic device company that has developed and is currently marketing the presbyopia-correcting Presbia Flexivue Microlens™, a miniature lens that is implanted in a corneal pocket created by a femtosecond laser. The Presbia Flexivue Microlens has received a CE mark for the European Economic Area, allowing the lens to be marketed in over 30 countries across Europe. A staged pivotal U.S. clinical trial for the Presbia Flexivue Microlens commenced in 2014.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160908005045/en/